Zydus Lifesciences inks pact with CVS Caremark

07 Jan 2025 Evaluate

Zydus Lifesciences has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet XR (Sitagliptin / Sitagliptin and Metformin Hydrochloride) tablets to its template formulary. CVS Caremark will add the company’s Zituvio and combination products to its template formulary starting January 1, 2025. 

Zituvio and combination products include Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets. These three NDAs of Sitagliptin (base) and combination franchise have been approved by the United States Food and Drug Administration (USFDA) earlier through the 505(b)(2) route. The Zituvio range of products contain active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

According to IQVIA (MAT August-2023), U.S. market for DPP-IV inhibitors and their combinations is $10 billion.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×